Verosudil（Cat No.:I009768）is a selective Rho-associated protein kinase (ROCK) inhibitor studied for its therapeutic potential in ocular and cardiovascular diseases. By inhibiting ROCK, it relaxes vascular smooth muscle, lowers intraocular pressure, and improves blood flow, making it a promising candidate for glaucoma and other optic neuropathies. Additionally, Verosudil has been explored for its role in vascular remodeling, endothelial protection, and anti-fibrotic activity. Its ability to modulate cytoskeletal dynamics and cellular contractility highlights its value in translational medicine, particularly in treating conditions driven by vascular dysfunction and tissue fibrosis.